Research programme: small molecule therapeutics - Janssen Biotech/Philogen
Alternative Names: Research programme: small molecules - Janssen Biotech/PhilogenLatest Information Update: 28 Dec 2025
At a glance
- Originator Janssen Biotech; Philogen
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for research development in Unspecified in Italy
- 28 Dec 2025 No recent reports of development identified for research development in Unspecified in USA
- 24 Nov 2021 Philogen and Janssen Biotech agree to co-develop small molecule therapeutics in USA and Italy for unspecified indications